J&J suffered another blow today as a key Remicade® (infliximab) patent was revoked by US Court of Appeals (Federal Circuit). Upholding the USPTO decision on reexamination of US 6,284,471, the Fed Cir held that the 35 USC §121 safe harbour does not apply, and the ‘471 patent was invalidated under the doctrine of obviousness-type double patenting (ODP).
The decision essentially makes redundant the pending appeal to the Fed Cir relating to the ‘471 patent in parallel proceedings initiated by Celltrion. Janssen appealed the August 2016 decision of the District Court (Massachusetts CA No 1: 15-cv-10698) which also revoked the ‘471 patent for ODP.
There are several infliximab biosimilar products already available in the US, although uptake has been slow. As previously reported, there is an ongoing dispute between Pfizer (Hospira) and J&J arising from Pfizer’s allegations that J&J’s anticompetitive conduct has improperly prevented biosimilar uptake.
Principal Lawyer, Patent Attorney, Trade Mark Attorney
Naomi is listed in IAM Patent 1000 as one of Australia's leading patent litigators, and in IAM Strategy 300: The World's Leading IP Strategists. Underpinning Naomi’s legal work is a deep understanding of the pharma/biopharma industries, resulting from first hand experience and knowledge as VP of IP in-house at global pharma giants, and Partner of a top-tier international law firm.